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Central venous catheters (CVCs) have a risk of infectious complications. With a 
suspected rise in cases in stem cell transplants, Eastern Health implemented two 
changes to reduce infections in June 2018: (1) earlier CVC insertion and (2) 
restriction of CVC access to specially trained nurses.  The primary outcome was 
the difference in rate of CVC-associated infections per 1,000 catheter-days. 
Secondary outcomes included identifying modifiable risk factors to target for 
future clinical interventions to lower complication rates. 
Methods: 
This single-centre observational before-and-after study included adult SCT 
patients with CVCs was divided into the pre- and post-intervention cohorts 
between 2014-2020. A complete chart review was conducted from the period of 
first CVC insertion through the endpoint of CVC removal or patient death to 
identify all incident cases of CVC associated infection, risk factors, cultures and 
90-day all-cause mortality.  
Results: 
The study demonstrated an incidence of catheter-related bloodstream infections 
(CR-BSI) of 21.3% in the pre-intervention group and 25.0% in the post-
intervention group (p=0.681). CR-BSI per 1000 catheter-days was similarly 2.39 
and 3.39 (p=0.628). Neither was statistically significant. The study identified a 
novel risk factor in preceding history of bacteremia (HR 763.1, p=0.039). In 
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conclusion we were unable to demonstrate a reduction in infectious 
complications associated with the two interventions. 
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Patients with blood and bone marrow cancers sometimes require stem cell 
transplants. These transplants require constant access to the patient’s blood 
vessels using a device called a central venous catheter (CVC) which carry a risk 
of infection. 
 
This study examined whether the restriction of access to these CVCs to trained 
nurses, as well as early insertion of the devices in the transplant process might 
reduce the risk of infection.  
 
We found that Eastern Regional Health Authority (Eastern Health) had a lower rate 
of infection than other centres. However, we did not find that the two interventions 
in the study were effective in lowering the rate of infection. The study confirmed 
two known risk factors for infectious complications: the type of device used and the 
site of insertion. The results also introduced a new risk factor: a previous bacterial 
infection of the blood. Finally, the study was able to contribute to an existing 
hypothesis that approximately half of bloodstream infections do not relate to the 
CVC but instead to breakdown in the gut of these patients due in part to the 
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Chapter 1: Introduction 
1.1 Central Venous Catheters 
Central venous catheters (CVCs) are a core component of the delivery of 
chemotherapy and other intravenous therapy in the management of 
hematological malignancies.1 These devices support the complex chemotherapy, 
stem cell transplant and supportive care required to manage advanced 
malignancies. They provide multiple lumens allowing simultaneous delivery of 
multiple therapies through a single port.  CVCs remain in situ for extended 
periods of time and reduce the need for repeated venipuncture and provide a 
convenient access point for blood draws.2   
 
CVCs are long thin tubes with multiple lumens which are inserted into a large 
vein, typically the right internal jugular (IJ) vein in the neck. They are typically 
placed under sterile conditions by an interventional radiologist or in the operating 
room by a surgeon or anesthesiologist. Placement involves two incisions, one at 
the site of the major vein being accessed and the second in the thoracic wall.3 A 
tunnel is then created through subcutaneous tissue between the sites allowing 
the CVC to exit at the latter incision site on the chest wall. The exit site is secured 
by means of a cuff under the skin.3  
 
There are a variety of classes of CVCs with multiple types of catheter within each 
class. Two varieties used in the SCT program at Eastern Regional Health 
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Authority (Eastern Health) in Newfoundland and Labrador are Hickman catheters 
and Permacath catheters. The Hickman catheter is a proprietary medical device 
developed by Robert O. Hickman in 1979 and features a tissue ingrowth cuff to 
secure it.4  Permacath is a proprietary silicon catheter used primarily for short-
term dialysis access (Figure 1.1). 
         Image Credit: BruceBlaus  is licensed by BY-SA 
 
Non-tunneled catheters are fixed in place directly at the site of insertion, while 
tunneled catheters pass the catheter under the skin.8 Peripherally inserted 
central catheters (PICCs) are inserted through a vein in the arm and advanced 
Figure 1.1: Central Venous Access Devices5,6,7 
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into a large central vein.8 These three classes leave a portion of the catheter 
exposed above the skin. An implanted port is a further class of device that buries 
the entirety of the apparatus under the skin (Figure 1.1).8  The devices utilized in 
the patient population for this study includes Hickman catheters, Permacath 
catheters and PICC lines. 
1.2 Infectious Complications 
CVCs carry a significant rate of complications including three types of infectious 
complication 
i) catheter-related bloodstream infections (CR-BSI),  
ii) catheter-related tunneled-line infections (CR-TLI), and  
iii) exit-site infections.    
These are significant complications with a reported mortality rate for CR-BSI in cancer 
patients of 12 to 40% per episode.9 Beyond the significant risk of mortality, infectious 
complications can impede care and lead to morbidity. The requirement to remove the 
CVC due to infection can delay treatment of the underlying malignancy and exposes the 
patient to the risks of reinsertion in a patient often at increased risk of bleeding due to 
thrombocytopenia.8  
The use of CVCs in other settings - particularly in the intensive care unit and 
solid tumor malignancies - has been robustly studied with meaningful reductions 
in complications such as CR-BSI.10,11 In the ICU setting the rate of infectious 
complications ranges from 3.8-11.3 events per 1000 catheter-day10,11 and in all-
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cancer populations the rate ranges from 0.02 to 3.2.14,15 The rate of CVC 
infection amongst SCT patients will be presented in the literature review section. 
CVC infection may require the removal of the CVC, which is a negative outcome. 
Ideally, the CVC will remain infection-free for the duration of the SCT period and 
be removed when no longer needed rather than be removed prematurely due to 
infection. 
1.3 SCT & Infectious Risk 
Hematopoietic SCT is the transplantation of pluripotent hematopoietic stem cells 
from the bone marrow, peripheral blood or umbilical cord blood.16 It is a 
procedure with significant risks, typically reserved for the treatment of cancers of 
the blood or bone marrow.16 Autologous SCT use stem cells are sourced from 
the patient, while allogeneic SCT use stem cells provided by donors.17 Eastern 
Health performs only autologous SCT locally, while allogeneic SCT are 
conducted at partner facilities in Eastern Canada. Hematological malignancies 
undergoing SCT at Eastern Health between 2013-2020 are detailed in Table 1.1. 
Evidence regarding the incidence and specific risk factors for CR-BSI in this 
subset of patients has begun to emerge in the last 15 years, though studies have 
utilized inconsistent methodologies and produced variable results particularly 




Table 1.1: Indications for Autologous Stem Cell Transplant 




Mantle Cell Lymphoma 
Grey Zone Lymphoma 
Diffuse Large B-Cell Lymphoma 
B-cell Non-Hodgkins Lymphoma 
Hodgkins Lymphoma 
T-Cell Lymphoma 
Primary CNS Lymphoma 
Anaplastic Large Cell Lymphoma 
 
Hematological malignancy has been established as an independent risk factor for 
the development of CR-BSI.18 These patients are at an increased risk of 
acquiring infection due to immunocompromise inherent in hematological 
malignancy, extended neutropenia induced through intensive chemotherapy, and 
increased requirement for blood products.19,20 Patients receiving SCT are a 
subset of hematological malignancy patients  who have a further 
immunocompromise due to therapy given to establish the transplant.21  
1.4 Study Purpose 
The Hematological Oncology service at Eastern Health in St. John’s, 
Newfoundland and Labrador became concerned with what they believed to be an 
increased rate of infectious complications in SCT patients with a CVC, beginning 
in mid-2017.  
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In June 2018 the Hematological Oncology service, working in conjunction with 
the Eastern Health Infection Prevention and Control Committee, implemented 
two interventions targeting a reduction in these rates. The first was a change in 
the timing of CVC insertion in SCT patients to minimize immunosuppression at 
the time of insertion. The second change was to nursing policy, limiting access to 
CVCs to trained in-patient nurses. These interventions are further delineated 
below.   
The purpose of this pre- and post-intervention cohort study is to investigate the 
baseline incidence, associated risk factors, causative organisms and mortality for 
CVC associated infections for hematological malignancy patients receiving 
autologous SCTs in Newfoundland and Labrador between January 2014 and 
June 2018. The study examined the post-intervention cohort to determine the 
effect of these interventions on the rate of CVC infectious complications in 
patients between June 2018 and March 2020. 
Intervention #1: Altering the Timing of CVC Insertion 
A single small trial of timing of CVC placement in patients with acute leukemia 
suggested that delayed insertion during the treatment period may be associated 
with increased rates of infection.22 Data was not available on timing of insertion 
and infectious risk in the SCT population. Previously at Eastern Health CVCs 
were inserted on Day 4-5 in the collection phase of transplant after the delivery of 
cytotoxic chemotherapy and immunosuppressive steroids. In the revised timing, 
 
7 
the CVC is inserted on Day -2 or -1 prior to the delivery of immunosuppressive 
therapy (Figure 1.2). The clinical team hypothesized that inserting the CVC while 
the patient's immune system is still relatively intact would reduce risk of infection. 
 
Figure 1.2 Transplant Timelines with Modified CVC Insertion Timing 
Intervention #2: Nursing Policy Change 
It was also identified that CVCs were being accessed by community nursing staff 
with variable levels of CVC training and experience during the interval between 
collection and transplant when the patient was seen as an outpatient. Adherence 
to Central Venous Access Device (CVAD) policy was unknown in this population. 
As such, the working group implemented an intervention of providing a clinical 
educator to review the existing CVAD policy with inpatient nurses and to restrict 
access to CVCs to inpatient and ambulatory treatment clinic nurses. 




To determine the effect of two interventions on the incidence, associated risk 
factors, causative organisms and all-cause mortality for CVC associated 
infections among hematological malignancy patients receiving SCT in 
Newfoundland and Labrador. 
Specific: 
Primary 
1. What is the effect on incidence per 1000 catheter days of CR-BSI, CR-TLI,  
exit-site infections and total CVC associated infectious complications  in adult 
hematological malignancy patients receiving SCT with a CVC placed in 
Newfoundland and Labrador between January 2014 and June 2020? 
Secondary: 
1.  What is the baseline incidence and incidence rate per 1000 catheter days of 
CR-BSI, CR-TLI, exit-site infections and total CVC associated infections in adult 
hematological malignancy patients receiving SCT with a CVC placed in 
Newfoundland and Labrador between January 2014 and June 2018? 
2. What are the associated risk factors of CVC associated infections in adult 
hematological malignancy patients receiving SCT with a CVC placed in 
Newfoundland and Labrador between January 2014 and June 2020? 
3. What is the all-cause inpatient mortality rate for adult hematological 
malignancy patient receiving once a diagnosis of CVC associated infection is 
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made for patients with a CVC placed in Newfoundland and Labrador between 
January 2014 and June 2020? 
4. Do hematological malignancy patients with autologous SCT and CR-BSI 
experience positive cultures for gut- associated bacteria (enteric Gram negative 
bacteria, streptococcus viridans)? 
1.6 Hypotheses 
Primary Hypotheses: 
1. Incidence Rate per 1000 catheter days 
❖ Ho=0 There is no difference in incidence rate per 1000 catheter days of 
total CVC associated infectious complications in adult hematological 
malignancy patients. 
❖ Ha≠0 There is a difference in incidence rate per 1000 catheter days of total 
CVC associated infectious complications in adult hematological 
malignancy patients. 
Secondary Hypotheses: 
1. Mortality  
❖ Ho=0 SCT patients with CVC associated infection do not have higher risk 
of all-cause mortality than those without infectious complication. 
❖ Ha≠0 SCT patients with CVC associated infection do have higher risk of 
all-cause mortality than those without infectious complication. 
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Chapter 2: Review of Literature 
2.1 Data Sources & Search Protocol 
The literature review was conducted of PubMed, EmBASE and Cochrane Library 
utilizing the MeSH terms (Hematologic* malignancy OR hematologic 
malignancies); AND (catheterization, central venous OR central venous 
catheterization) AND infection AND sepsis AND incidence AND risk factor*. The 
search strategy filtered results for human studies in English for participants 19+ 
years of age. No time limit was placed on the search. Studies included in the 
search were systematic reviews, meta-analyses, randomized control trials, 
prospective and retrospective cohort studies and case series. References for 
relevant papers were reviewed to identify any additional studies of interest. 
2.2 Background Information 
The literature review identified five cohort studies that examined the 
epidemiology of CVC infectious complications in adult hematological malignancy 
patients.20,21,23-25 There was a high degree of variability in the study designs. The 
study designs were mixed in terms of patient populations with some studies 
including only SCT patients21, some excluding SCT patients20,  and others 
examining all hematological malignancy patients.21,23-25 These subgroups are 
highly variable in the characteristic of their underlying malignancy, the degree of 
immunosuppression related to SCT preparation and maintenance, and the 
chemotherapy delivered. The studies also had a mix of primary outcomes with 
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most studies looking exclusively at CR-BSI.21,23,24 While one study examined all 
CVC infectious complications, it did not provide a separate incidence for each 
subtype.25 Worth et al examined both CR-BSI and exit-site infections but did not 
report on CR-TLI.23 The overall infectious complication incidence in these studies 
ranged from 24.7-31.3% per CVC line placed, significantly higher than rates 
quoted for non-hematological malignancy CVC patients.12-15 Only three studies 
reported incidence rate per 1000 catheter days. The range for these results 





Four studies examined risk factors associated with CVC infectious complications 
among adults with hematological malignancy.20,21,23,27 All these studies looked at 
associations with CR-BSI only. The reported risk factors are often in conflict and 
no study replicated a single risk factor identified in another study. In some 
instances, risk factors that would seem to be clinically relevant were not found to 
have an association (neutropenia, length for time in-dwelling). Others like Girard 
Table 2.1: CVC Infectious Complications in Hematological Malignancy Literature Review Summary
Study Design Population Outcome Incidence













Adult AML + MDS with 
Allogeneic SCT
CR-BSI 32% Not reported






















et al.'s finding of lymphoma as an associated risk factor are out of step with all 
previous studies (Table 2.2).12 
 
Helpfully, the studies highlight some under-investigated markers of 
immunosuppression which this study will include: corticosteroid burden and 
erythropoietin administration. Corticosteroids had been previously identified as a 
risk factor for infection when used for treatment of graft-versus-host disease in 
allogeneic SCT patients, however data was not available assessing it as a 
baseline risk factor in all SCT patients.28 The study by Girard et al. is the only 
Table 2.2: Risk Factors Associated with CR-BSI in Hematological Malignancy



































available data on erythropoietin use and infectious complications in the literature 




Chapter 3: Methods 
3.1 Research Setting 
The study was conducted at the Health Science Centre in St. John's, 
Newfoundland and Labrador. This is the single SCT centre for the province and 
provides autologous SCT. Patients requiring allogeneic SCT are referred out of 
province for completion of their procedures. Transplant patients are not 
discharged with CVCs in place, meaning that all data relevant to the study was 
contained in the patient chart for a single admission to hospital.  
3.2 Data Sources 
Study participants were identified through the Newfoundland and Labrador Stem 
Cell Transplant and Hematological Malignancy Patient Registry as detailed 
above. Data was generated from patient charts accessed through the Eastern 
Health Meditech system, or where paper records were required through the 
Eastern Health Health Information Services and Informatics department. 
3.3 Study Design 
Similar to most studies examining infectious complications in CVCs in 
hematological malignancy this study is a single-centre descriptive cohort study. 
The group of interest in this study is adult hematologic malignancy patients 
undergoing SCTs. The study compares the population prior to two policy 
interventions targeting a reduction in rates of CVC associated infectious 
complications (Figure 3.1). The study was restricted to inpatients given the wide 
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disparity in infectious complications in outpatient hematology patients with central 
lines reflective of lower underlying immunosuppression from both disease and 
treatment characteristics.26  
 
Figure 2.1 Study Timeline 
All consecutive SCT patients who underwent CVC placement for inpatient 
treatment between January 2014 and June 2020 were included in the study. The 
group of interest represented approximately 25 autologous SCT patients per year 
with an increasing annual rate of SCT throughout the study period. These 
patients are registered in the Newfoundland and Labrador Stem Cell Transplant 
and Hematological Malignancy Patient Registry maintained by the Hematological 
Oncology group at Eastern Health and were identified by querying the registry for 
new patients in the timeframe of the study. Only patients with elective or semi-
elective CVC placement under radiologic guidance were included in this study. 
Emergently placed lines are placed in uncontrolled conditions in comparison to 
planned line placements performed by interventional radiology. Emergently 
placed lines occur when patients are unwell, may occur in environments such as 
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the emergency department or intensive care unit, and are not typically performed 
by an interventional radiologist. Infectious risks are higher during these 
procedures and as such lines placed emergently or in the intensive care unit 
(ICU) setting are excluded. 
3.4 Study Procedure 
The principal investigator reviewed the patients identified through the patient 
registry for inclusion and exclusion criteria as described below. Patients meeting 
the criteria underwent a chart review by the principal investigator. Any data from 
the chart review that was clinically ambiguous regarding an infectious outcome 
as defined in the- study was anonymized then reviewed by the Infectious 
Disease Specialist and the Hematologic Oncologist. A decision was made by 
interpreting the available clinical data, applying the relevant study definition and 
classified as either a type of infectious complications, as a non-event, or as 
unable to evaluate. A sensitivity analysis was planned to evaluate data with 
cases deemed unable to evaluate as infectious complications and as non-events 
however no such event occurred in the chart review. 
Patients were followed until the CVC was removed either: i) at the conclusion of 
treatment, ii) due to complication, or iii) death. Ninety-day mortality was 
documented for each patient from the time of line removal. For patients who had 
a CVC replaced, the new CVC was included as a discrete CVC for the purposes 
of infectious complication incidence, risk factors and microbiology cultures 
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calculations. For mortality, the denominator utilized is total patients rather than 
total lines placed. 
3.5 Study Participants 
 
Table 3.1: PICO Question 
3.6 Outcome Definitions 
3.6.1 CR-BSI 
There is not currently a consensus regarding the surveillance definition of CVC 
infectious complications in the literature - not only for hematologic malignancy 
patients, but in other settings as well.29 Further, clinical definitions of CVC 
associated infection differ from surveillance definitions. Clinically, other sources 
of infection are sought by patient examination, laboratory evaluation and chart 
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review. If an alternate source for infection cannot be identified, then it is often 
attributed to the CVC without definitive evidence. This is particularly the case for 
bacteremia without source in the surveillance definitions.  If the CVC is pulled a 
culture of the catheter tip is performed to confirm CVC implication in the 
infection.29 In this population the practice is often to attempt to preserve the CVC 
in situ through the treatment of underlying infection. This makes it impossible to 
fulfill the “definitive” criteria in the surveillance definitions for infectious 
complications, which include culture results from the CVC tip after removal.  
A summary of the surveillance definitions utilized for CR-BSI in the literature is 
below, further complicated by the 2013 introduction of the modified CDC 
definition which excludes bacteria likely of a gastrointestinal source in 
hematology patients.30  
The surveillance definitions from the United States are stringent and offer the 
best evidence for proving a CVC infectious complication. However, the local 
microbiology laboratory does not report culture results quantitatively nor include 
time to growth, therefore these definitions cannot be utilized in this chart review. 
Therefore, the Public Health Agency of Canada definitions will be used in this 
study, which is consistent with the existing Infection Control definition used at 




Table 3.2: Surveillance Definitions of CR-BSI (CDC - Centre for Disease Control, CFU - Colony Forming Unit, IDSA - 
Infectious Disease Society of America, BSI - Blood Stream Infection) 
3.6.2 Exit Site Infections 
Exit-site infections are complications that occur at the level of the skin where a 
device exits the patient. This study will follow the CDC definition of erythema or 
induration within two centimeters of the catheter exit site in the absence of 
concurrent BSI and without purulence.30 
Table 3.2: CR-BSI Surveillance Definitions
Organization Defintion
Clinical manifestations of infection
At least 1 positive blood culture from a peripheral vein with either positive 
semiquantitative (>15 CFU/catheter segment) or quantitative (>103 CFU/catheter 
segment) from a catheter tip with the same species and antibiogram
OR
Simultaneous quantitative cultures of blood samples (catheter v peripheral) with a ratio 
of >3:1
OR
Differential period to culture positivity for catheter v peripheral of 2 hours 
OR 
Positive blood culture + symptoms of BSI AND no identifiable source
Positive peripheral blood culture + symptoms of BSI AND no other identifiable source
AND one of the following
At least 1 positive blood culture from a peripheral vein with either positive 
semiquantitative (>15 CFU/catheter segment) or quantitative (>103 CFU/catheter 
segment) from a catheter tip with the same species and antibiogram
Simultaneous quantitative cultures of blood samples (catheter v peripheral) with a ratio 
of >5:1
Differential period to culture positivity for catheter v peripheral of 2 hours 
Definite: Single positive blood culture and positive culture of exit site or tunnel exudate 
with identical organism
OR
Single positive blood culture and positive culture from catheter tip with identical 
organism or >10-fold colony count difference in tip v. peripheral blood
Probable: >1 positive blood culture with no evidence of source other than CVC
OR









Tunnel infections are complications which occur in the subcutaneous tissue 
where the device travels under the patient's skin. This study again employs the 
CDC definition of tenderness, erythema or site induration greater than two 
centimeters from the catheter site along the subcutaneous tract of a tunneled 
catheter, in the absence of concomitant BSI.30 
3.7 Randomization and Blinding 
In the context of a retrospective study, there is no randomization of study 
participants to exposures. However patient demographics were analyzed to 
ensure the group of interest and comparison groups are sufficiently similar to 
allow for statistical comparison. 
Considering the nature of chart reviews with clinical data rife with personal 
identifiers it will not be possible to blind the research assistant in the process of 
data collection. Data was anonymized as it was entered into the database. Upon 
completion of the data collection phase the groups, risk factors and microbiology 
culture results were blinded through use of randomly generated labels. The 
principal investigator maintained a key in an encrypted, password protected file 
for unmasking once data analysis is complete. 
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3.8 Research Team 
Given the scope of this study a multidisciplinary team has been assembled. All 
members completed the Tri-Council Policy Statement 2 (TCPS-2) Core training 
module prior to initiation of the study.  
Core Team: 
The Principal Investigator (PI) has ultimate responsibility for the conduct of the 
study. The PI obtained approval from the Health Ethics Research Board. He was 
be responsible for acquiring access to patient charts, for implementing study 
protocols for interpretation of clinical data, data management, data analysis and 
for dissemination of study results. The author served in this capacity for this 
study. 
A Clinical Hematological Oncologist (CHO) is responsible for coordinating 
access to the Newfoundland and Labrador Stem Cell Transplant and 
Hematological Malignancy Patient Registry to identify patients treated at the 
Health Science Centre. The CHO was responsible to acquire informed consent 
when not established in the course of treatment. The CHO served in conjunction 
with the Infectious Disease Specialist representative to evaluate and adjudicate 
clinical data from patient charts to match study outcome definitions in accordance 




An Infectious Disease Specialist (IDS) from the Eastern Health Infectious 
Disease department assisted in the development of study definitions for CR-BSI 
and CR-TLI. The IDS was responsible to adjudicate any ambiguous clinical data 
with the CHO as described above. The IDS assisted in interpretation of culture 
results from the microbiology laboratory to ensure that contaminants are not 
included in study results. Dr. Peter Daley served in the capacity of IDS for the 
duration of this study. 
A Clinical Epidemiologist (CE) acted as the primary advisor on study design 
particularly in establishing protocols for data interpretation and establishing clear 
outcome definitions. Dr. Kathy Hodgkinson served in the capacity of CE for the 
duration of this study. 
3.9 Statistical Analysis 
3.9.1 Data Analysis 
 
Descriptive analysis was conducted to calculate incidence and incidence rate per 
1000 catheter days for exit-site infections, tunneled-line infections and CR-BSI, 
then in aggregate for all infectious complications. The denominator for incidence 
is total CVC placed, and for incidence rate is total in-dwelling days.  
Univariate analysis was conducted utilizing the t-test for continuous variables and 
Chi-squared test for categorical variables to identify risk factors. Multivariate 
analysis was conducted utilizing binary logistic regression with an entry criterion 
for Odds Ratios (OR) of p≤0.20 with reverse stepwise removal of insignificant 
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variables. A p-value of <0.05 was considered an indication of statistical 
significance. Confidence intervals of 95% were calculated. All statistical tests 
were two-sided. Risk factors assessed in the study are below (Table 3.3).  
Days to infectious complication was calculated using the Wilcoxon rank-sum test. 
An analysis of catheter survival (catheter remains in-dwelling) was performed 
using a Kaplan-Meier curve for the study population as a whole and for patients 
who experienced an infectious complication. All-cause 90-day mortality was 
planned to be calculated using the Kaplan-Meier curve, however as only a single 
event occurred in the study period there is not sufficient data for reliable analysis. 
Risk factor analysis as described above was planned to be re-calculated for all-
cause 90-day mortality, however this too did not proceed due to too few events in 
the study period. 




3.9.2 Sample Size 
Existing studies in the literature are all cohort studies without comparison groups, 
and as such do not provide sample size calculations. A power analysis utilized 
below estimates the sample size required to test the difference in incidence of 
catheter-related infectious complications before and after the implemented 
interventions. The level of significance for this study is 5% or α = 0.05. The power 
is 90% or β = 0.10. An expected effect size of 30% in incidence rate per 1000 
catheter days comparing the pre- and post-intervention cohorts was determined 
to be clinically relevant in this population. The clinically estimated incidence rate 
based on observation is approximately twice the rate at other centres. As noted 
Table 3.3: Risk Factors to be Assessed for CVC Infectious Complications in Hematological Malignancy
Risk Factors Categorical Continuous
Previously Identified Risk 
Factor
Age x
Malignancy Diagnosis x x
Transplant Status x
History of previous bacteremia x
History of previous fungal infection x x
HLA match v. mismatch x
Chemotherapy type x
Number of prior chemotherapy regimens x
Corticosteroid burden last 90 days x
Erythropoietin use x x
Days until PMN>500µL x
Central line type x x
Insertion site x x
Antibiotic prophylaxis x
Training level of Radiologist (Resident/Staff) x
Day of week of insertion x







previously, the incidence of catheter-related infection in SCT patients is 32% per 
CVC placed thus for this population we will use an event rate of 64%. The 
standard deviation of incidence rate per 1000 catheter days is 0.6.17,18,20,24  
 n = 2(Zα + Z1-β)2σ2/Δ 2= (2(1.96+1.2816)2(0.12)2/(0.3)2 = 84.1 
The calculated study sample size is 84.1 patients. Given the study design and 
noting that all patients enrolled are inpatients for the duration of their treatment 
and have their CVCs removed prior to discharge, loss-to-follow-up should be 
minimal in this study. Estimating a 10% loss of follow up, a total of 92 samples 
will be required.  
 
Subsequent to the completion of this power calculation the study committee 
reviewed the size of the overall population. Given the limited number of patient in 
the pre-intervention period spread over a significant period of time, and the 
possibility that the rise in infectious complications were clustered within the 2017-
2018 timeframe as suspected based on clinical observations, a decision was 
made to include all 94 patients in the pre-intervention time period to allow for a 
more robust cohort and strengthen the certainty of any effects detected. The 
power calculation was utilized to determine the number of patients in the post-
intervention period would be required to detect the effect as described above and 
to determine when enrollment was complete. 
 
27 
3.9.3 Patient Enrollment & COVID-19 
Patient enrollment proceeded as planned for the pre-intervention group as all 
patients had completed treatment prior to the initiation of data collection. Patients 
in the post-intervention group were enrolled consecutively as SCTs were 
completed. This continued until the end of February 2020. In March 2020 the 
Eastern Health SCT program was suspended given the infectious risk to patients 
related to the COVID-19 (Coronavirus disease 2019) global pandemic. 
 
In light of this complication the supervisory committee for this thesis met and 
agreed to suspend data collection. At that point 32 patients had been enrolled in 
the post-intervention group, or 69.6% of the planned enrollment to meet power 
calculations. While acknowledging that cessation of data collection at this point 
would result in an underpowered study, the committee felt it best to proceed with 
data analysis to deliver some preliminary conclusions given that a resumption 
timeframe was not yet determined for the SCT program. 
 
Finally, the principal investigator has arranged for data collection to continue with 
the resumption of the SCT program through a new principal investigator. This will 




Chapter 4: Results 
4.1 Patient Characteristics 
In the pre-intervention period between January 2014 - June 2018 95 charts were 
included in the study for review. Of those 95 charts there were 94 individuals 
planned for autologous stem cell transplantation. Seventy-five (75) patients were 
included in the pre-intervention cohort. Of the 19 exclusions there was one (1) 
duplicate record, one (1) SCT for a non-hematologic malignancy, and eight (8) 
patients who underwent stem cell collection only and did not proceed to 
transplant. In 2014 there was a period of time when autologous transplants were 
not conducted locally, and patients were transferred out of province for 
transplant. Nine (9) patients were excluded from this study who underwent out-




  Figure 4.1: Study Population Inclusion and Exclusions 
 
The post-intervention period spanned from July 2018 - March 2020 when the 
SCT program was suspended due to the COVID-19 global pandemic. During this 
period charts from 35 consecutive planned SCTs were reviewed. Three (3) 
patients were excluded from this cohort as they only underwent stem cell 
collection and did not proceed to transplant. 
 
The pre- and post-intervention groups demonstrated some differences in 
baseline characteristics. As consecutively enrolled patients representing the 
entire population for each cohort these differences cannot be explained by 
randomization. In terms of patient characteristics there were more males in the 
post-intervention group (71.9% versus 55.8%, p=0.11), they had less myeloma 
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(53.1% versus 61%, p=0.459) and more diffuse large B-cell lymphoma (DLBCL) 
(25% versus 15.6%), had less history of bacteremia (3.1% versus 16%, p=0.002) 
and less history of radiation therapy (6.3% versus 19.5%, p=0.038) (Table 4.1).  
 
In terms of CVC characteristics, the post-intervention group had less antibiotic 
prophylaxis prior to line placement (0% versus 16.9%, p=0.013), less use of 
heparin-impregnated CVCs (25% versus 45.5%, p=0.038) and fewer days 
indwelling (78.73 versus 89.33, p=0.595). Both populations were approximately 
equivalent in the distribution of types of CVC, number of lines of chemotherapy, 







4.2 Infectious Complication Incidence and Incidence Rates 
4.2.1 Incidence Rate 
 
The incidence per 1000 catheter days of infectious complications under the CDC 
and Public Health Agency of Canada definitions outlined above were compared 
between the pre- and post-intervention groups. No statistically significant 
difference was detected in the total incidence rate of infections per 1000 catheter 
days, or for any of the subtypes of infectious complications. While total infections 
per 1000 catheter days showed a non-significant improvement from 6.87 to 5.5 
(p=0.763), this was derived entirely from exit site infections which carry the 
lowest clinical impact. CR-BSI and CR-TLI showed non-significant increases in 
incidence rate per 1000 catheter days. 
4.2.2 Incidence 
No statistically significant difference was detected in the total incidence of 
infectious complications or any of the sub-definitions between the groups. 
 
The incidence of total infectious complications in the pre-intervention group was 
46 cases (59.7%), while in the post-intervention group it was 13 cases (59.4%).  
The incidence of total CR-BSI in the pre-intervention group was 16 (21.3%), in 




Exit site infection incidence trended toward a statistically significant reduction, 
with 16.9% in the pre-intervention group and 6.3% in the post-intervention group 
(p=0.07) (Table 4.2). 
 
 
4.2.3 Post-Hoc Review of Incidence and Incidence Rates 
In reviewing the data, the failure to identify a difference in incidence and 
incidence rate in CVC-associated infectious complications did not seem 
consistent with what was believed to be an observed increase in this population 
amongst clinicians. It was proposed that the increase may have been limited to a 
shorter interval than total pre-intervention period spanning from mid-2017 to June 
of 2018 when these interventions were put in place. The original pre-intervention 
cohort timeframe was selected to ensure a large enough population to satisfy the 
power calculations and in light of the overall small population size. A post-hoc 
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Poisson analysis was conducted comparing these periods (January 2014-June 
2017, July 2017-June 2018, July 2018-March 2020) (Figure 4.2).  
 
Figure 3.2 Study Timeline with Post-Hoc Analysis 
This post-hoc Poisson analysis was conducted for total infectious complications 
per 1000 catheter-days. The rates were 2.21, 10.84 and 5.50 per 1000 catheter-
days respectively. No statistically significant differences were found between the 
groups (p=0.34), however these differences were highly clinically significant. 
 
An ANOVA (analysis of variance) demonstrated incidence of total infectious 
complications of 28.3%, 63.4% and 40.6% for these timeframes. The analysis 
revealed a significant difference in the incidence of the sub-divided pre-
intervention group with a mean difference of 35.3% (95% CI 0.06-0.65, p=0.013). 
The timeframe was explanatory for just 7.6% of the variance between these 
subgroups. No other statistically significant differences in incidence were found.  
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4.3 Risk Factors for CR-BSI 
4.3.1 Patient Related Risk Factors 
Eleven patient-related predictors were included in the univariate analysis, and 1 
was statistically significant. Patients undergoing SCT with only a single previous 
line of chemotherapy had a hazard ratio of 0.114 (p 0.001). Total 90-day 
prednisone-equivalent corticosteroid dose and use of erythropoietin were not 
significant. (prednisone p=0.659, erythropoietin p=0.479). Multivariate analysis 
showed a history of bacteremia as a significant risk factor for CR-BSI with an OR 
763.1 (95% CI 1.4-417589.9, p=0.039). Prednisone dose did trend toward 






4.3.2 CVC Related Risk Factors 
Eight CVC-related predictive factors were included in univariate analysis, and two 
were statistically significantly associated with CR-BSI. A significant protective 
association between Permacath type CVC and CR-BSI (HR 0.03, 95% CI 0.004-
0.295, p =0.002) was identified. Likewise, there was a significant protective 
association between right IJ placement of the CVC and CR-BSI (HR 0.048, 95% 
CI 0.006-0.413, p=0.006). This is consistent with this location as a clean site 
predominantly selected as the insertion point in SCT patients as well as ICU and 
hemodialysis.  
 
Neither antibiotic prophylaxis nor heparin-impregnation of the CVC demonstrated 
any association with CR-BSI despite their routine use as a prevention 
mechanism by some interventional radiologists. Additionally, a preceding exit-site 
infection or tunneled-line infection had no association with the development of 
CR-BSI. 
 
Multivariate analysis revealed a weak protective association for total days CVC 
indwelling (OR 0.94, 95% CI 0.896-0.986, p=0.011). Preceding exit site infection 




4.4 90-Day Mortality 
Throughout the entire study period only a single death occurred in the 90-day 
follow-up period. The rarity of this event is decidedly below the expected rate and 
limits the statistical analysis planned. The death observed occurred in the pre-
intervention group and thus generates a statistically significant difference in the 
rate between groups, however this cannot reliably be assessed (Table 8). 
 
4.5 CVC Line Survival Comparison 
A Kaplan-Meier survival curve was generated to demonstrate the survival period 
of CVCs between the pre- and post-intervention cohorts. The resulting curves are 
below, demonstrating no difference in CVC survival. The pre-intervention cohort 
has two outliers with extremely prolonged periods with the same CVC remaining 
indwelling (more than 1400 days in one case) related to either delayed SCT or 
lines placed primarily for hemodialysis. A sensitivity analysis was performed 
removing the two longest periods for the pre-intervention group without a change 





Figure 4.3: Total CVC Survival Kaplan-Meier Curves for Pre- and Post-Intervention Cohorts 
 
The two curves do separate early suggesting there may be some improvement in 
CVC survival in the post-intervention group. However, by day 80 the curves 
overlap. The Mantel-Cox analysis did not show a significant difference between 
the two curves (p=0.822). 
 
A second Kaplan-Meier analysis was conducted comparing CVC survival in 
patients with infectious complications against those without. The resulting curves 
are presented below. As expected, patients without line infections are able to 
maintain their central venous catheters for significantly longer periods of time 




Figure 4.4: Total CVC Survival Kaplan-Meier Curve Comparing No Infection Versus Infectious Complication 
4.6 Time from CVC Insertion to CR-BSI 
An inverse Kaplan-Meier analysis was conducted to compare the time from CVC 
insertion to CR-BSI detection. The resulting curves show a significant difference 
between time to onset of infection (p = 0.003). The curves separate early and 
remain separate throughout the observation period. The first infectious 
complication in the post-intervention group occurred 46 days from CVC insertion, 
meanwhile 14/16 (87.5%) of infectious complications had occurred by that point 





Figure 4.5: Onset of CR-BSI from CVC Insertion Comparing Pre- and Post-Intervention Cohorts 
4.7 Time from SCT to CR-BSI 
A similar inverse Kaplan-Meier analysis was performed to compare time from 
SCT to CR-BSI. The analysis excluded two cases where patients experienced an 
infectious complication in the stem cell collection phase prior to SCT. Both of 
these events occurred in the pre-intervention period in the period of highest 
concern for increasing incidence of infectious complications (July 2017-June 
2018). These events occurred 39 and 43 days prior to SCT. 
 
The resulting curves are presented below. There was no significant difference 





Figure 4.6: Days from SCT to CR-BSI Comparing Pre- and Post-Intervention Cohorts 
4.8 Causative Pathogens and Modified CR-BSI 
The etiologies of CR-BSI in the total study population are separated in table 9 
into two groups of bacteria. There were an equal number of infections caused by 
these two groups.The first are those typically associated with skin and soft tissue 
infections that might be considered high risk for causing a CVC-associated 
infectious complication. The organisms identified in this group are 
Staphylococcus aureus (6), coagulase negative Staphylococcus (3), Rothia (1), 
Staphylococcus lugdunensis (1) and Staphylococcus epidermis (1).  
 
The second group are Gram-negative organisms and those typically found in the 
oropharyngeal or gastrointestinal tract of humans. It has been proposed that 
these organisms are more likely to cause a bloodstream infection through an 
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interruption of the mucosal barrier, as opposed to causing a bloodstream 
infection by entering the CVC. This is typically considered a complication of graft-
versus-host disease, though it can also be caused by chemotherapy, radiation 
and conditioning agents used in the preparation for SCT.27 When there is no 
complaint or examination finding representing gastrointestinal involvement and 
these organisms are detected, surveillance definitions continue to include them 
as probable CR-BSI. A previous epidemiological study of CVC infectious 
complications in SCT patients by Leukenbill et al. proposed a modified definition 
of CR-BSI to exclude these organisms.21 The organisms in this category 
encountered in this study population are Escherichia coli (6), Pseudomonas (2), 
Haemophilus influenzae (1), Streptococcus salivarius (1), and Klebsiella 
pneumoniae (2) (Table 4.5). 
Table 4.5: Causative Organisms by Blood Culture    
Causative Organism   
Total 
Cases Percentage Cumulative 
Skin Flora   12     
Staphylococcus Aureus  6 25 25 
Coagulase Negative Staphylococcus  3 12.5 37.5 
Rothia  1 4.2 41.7 
Staphylococcus lugdunensis  1 4.2 45.9 
Staphylococcus epidermis  1 4.2 50.1 
Oropharyngeal & Gastrointestinal Flora   12     
Escherichia coli  6 25 75.1 
Pseudomonas  2 8.3 83.4 
Haemophilus influenzae  1 4.2 87.6 
Streptococcus salivarius  1 4.2 91.8 






The study by Leukenbill et al. suggested that the reported incidence of CR-BSI 
could be reduced by 25.8% if the organisms were removed per the modified 
definition.21 In our study population the incidence of CR-BSI would be reduced by 
50% to 11.2% if organisms were removed per the modified definition (Table 4.6). 
 
Table 4.6: Incidence of Total CR-BSI for the Total Population   
    
Incident 
Cases Incidence 
Original Definition of Positive Blood Cultures  24 22.4% 
Modified Definition of Positive Blood Cultures  12 11.2% 
 
In cases where culture results represented infections typically associated with 
skin and soft tissue the mean length of CVC survival was 7.25 days from positive 
blood culture. In comparison the mean length of CVC survival in patients with 
organisms excluded under the modified CR-BSI definition was 20.25 days. This 





Chapter 5: Discussion 
5.1 Efficacy of Interventions in CVC Infection Prevention 
Clinicians suspected an increase in the rate of total infectious complications in 
SCT patients associated with CVCs in mid-2017 for a period extending to mid-
2018. ANOVA analysis of these periods confirms that the rate of incident cases 
did indeed increase during this period, more than doubling from 28.3% to 63.6%. 
No clear change was identified to explain this rise in incident cases of infectious 
complications in this time period. A comparison of the pre-intervention cohort with 
the post-intervention cohort was unable to demonstrate a reduction in incident 
cases with the dual intervention of a change in timing of CVC insertion and a 
restriction in nursing access to CVC devices. 
 
The incidence of CR-BSI infections at this institution were 21.3% and 25.0% in 
the pre- and post-intervention cohorts. Both groups were similar to the incidence 
identified in the literature review of 24.7-32%.20,21,23,24,26  
 
Analysis of the rate of infectious complications per 1000 catheter days did not 
demonstrate significant change in the incidence rate with the introduction of the 
dual interventions. The non-statistically significant improvement in total infectious 
complications is almost entirely attributable to the improvement in exit site 





Although a significant difference was not observed in infection rate, the 
interventions were associated with an increase in the survival time of the CVC. 
CVC survival time is a surrogate for infection risk, although CVC survival time is 
also influenced by the clinician’s decision to remove the CVC, and this decision 
may not correlate with infection rate. 
 
The pre-intervention CR-BSI incidence rate in the study was 2.39 per 1000 
catheter days while the post-intervention group rose to 3.39. The rate for the 
entire study population is 2.65 CR-BSI per 1000 catheter days. These incidence 
rates are much lower than the lowest rates identified in the literature review (5.2-
7.5 per 1000 catheter days).20,21,23,24,26 Other study populations have significantly 
different baseline characteristics, most notably the studies include allogeneic 
SCT while this centre only include autologous SCT. 
 
While we observed no difference in the overall length of CVC survival between 
the pre- and post-intervention cohorts, we were able to detect that line removal 
was significantly delayed in patients who developed infectious complications. 
Discussions with clinicians and qualitative review of documentation in patient 
charts revealed no overt change in clinical practice to delay the removal of CVCs 




Perhaps then a closer look at the specific interventions might help explain this 
change in duration of CVC survival from CVC placement. The first intervention 
that moves forward in time CVC insertion by 4-5 days to a period of relatively 
less. This period represents 11.1% of the longer CVC survival from CVC 
placement. It may also be that any transient bacteremia that may occur in the 
process of CVC insertion is overcome by the immunocompetent patient without 
overt infection in the post-intervention cohort. Unfortunately, the data such as 
routine post-CVC placement blood culture were not available in the chart review 
did not allow further analysis of this hypothesis. 
 
The second intervention restricted nursing access to those nurses with advanced 
training in how to sterilely access CVCs. In the pre-intervention group any access 
to a CVC by a nursing professional without advanced training would have been 
likely to occur in the first days or weeks after line placement while the patient 
remained in the community prior to admission for SCT. This may explain in part 
why CR-BSI resulted in earlier CVC termination, however little documentation 
existed in patient charts regarding any out-of-hospital CVC access preventing 
analysis to support this hypothesis.  
 
In addition, at the introduction of these policy changes inpatient nurses were 
made aware of the concern for infectious complications and the changes being 
made to nursing practice. This knowledge that there was concern and ongoing 
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monitoring may have enacted the Hawthorne effect contributing to the change in 
incident rate. 
5.2 Risk Factors For CR-BSI 
Previous epidemiologic studies of CVC infectious complications in the SCT 
population have been inconsistent in the risk factors identified. Girard et al., had 
identified a particular type of CVC, the Groshong catheter, as a risk factor for 
infection (RR 5.75).26 This device is not used at our centre. Our study did not 
identify any particular device as a risk factor but did find that PermaCath devices 
to have a protective effect (OR 0.03 95% CI 0.004-0.295, p=0.002). PermaCath 
is the predominant device used at this centre for this indication for CVCs and 
reduced complications may be a feature of the small population size or 
radiologist and nurse familiarity with the device rather than device characteristics. 
 
Most CVCs are placed at the right internal jugular vein (IJ). This location is easy 
to access and clean once the CVC is placed in comparison to other access 
points such as the inguinal veins. The CVC insertions in this study were 
completed under controlled conditions. The only cases where alternate sites 
were used were because of anatomical variations, compromise of the right IJ due 
to previous CVC placement, or thrombotic complications at that site. The right IJ 
site was demonstrated to be protective for infectious complications with a hazard 
ratio of 0.05 (95% CI 0.006-0.413, p=0.006). This supports a previous finding by 
Dix et al. which showed a similar protective effect at this site.20 No study has 
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shown a particular insertion site to be associated with increased rates of 
infectious complication. 
 
A study by Worth et al had previously shown a positive association between a 
history of fungal bloodstream infections and future CVC associated bloodstream 
infections.23 In our population previous fungal infections were a rare event with 
only one identified through the chart review. We therefore found no such 
association in our study. We did, however, identify a history of bacterial 
bloodstream infection as a significant risk factor in multivariate analysis with an 
odds ratio of 763.1, though with an extremely wide 95% confidence interval (1.4-
417,589.9, p=0.039).  Given that our study is small and underpowered it is 
difficult to confidently attribute such a strong odds ratio to this risk factor that has 
not been previously reported. It is, however, a point for future investigation. A 
more detailed charting process may be able to identify whether particular 
organisms or sources of bloodstream infections point towards re-infection risk. 
 
Authors of previous studies of risk factors of CR-BSI postulated that degree of 
steroid exposure may be a predictor of infection. No study had previously 
examined this risk factor. In our study we choose to examine the total 
prednisone-equivalent dose received over a 90-day period. This dosing was 
highly variable as significant steroid doses are included in almost all 
chemotherapy regimens prior to SCT. Patients who received their final cycles of 
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chemotherapy close to transplant had high steroid burden. Steroid is part of the 
conditioning therapy for SCT and often dose reduced in frailer patients, or 
patients who do not tolerate steroid. As a variable thought to predict 
immunocompromise with escalating doses, smaller doses may in fact reflect a 
more physically compromised host. Our study was unable to show an effect of 
steroid dosing and infectious complication. 
 
Girard et al. had also previously identified erythropoietin use as a risk factor for 
infectious complication.26 Erythropoietin is a hormone that promotes red blood 
cell production. The authors postulated that it may be a marker for overall 
hematopoiesis suppression and patients who may not be able to mount an 
immune response to infection. Our study was unable to replicate this risk factor, 
though the confidence interval was again wide and may reflect a study population 
too small to detect the effect (HR 2.07, 95% CI 0.277-15.44, p=0.479). 
 
Overall the study was able to identify only two modifiable risk factors, both with 
protective effect - right IJ site for insertion and use of a PermaCath. These are 
both essentially standard of care at our centre already and do not represent 
significant opportunities for improvement in practice. The results do encourage 
more vigilance in looking for signs of infection in patients with a history of 
bloodstream infection. Further work with larger sample sizes may also help to 
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demonstrate whether antecedent infections such as exit site and tunneled-line 
infections are risk factors for CR-BSI. 
5.3 Causative Organisms and Modified Definitions for CR-BSI 
Like the study by Lukenbill et al., our study has identified that a significant 
number of the infections attributed to the CVC under the current surveillance 
definitions are not caused by skin flora. It also appears that clinical practice 
attributes these blood culture results in a similar manner, choosing to preserve 
CVCs for longer in patients with these culture results (mean difference 13.0 days, 
p=0.07). It is also important to note that additional positive blood culture results 
with organisms from the oropharyngeal and gastrointestinal tract were excluded 
from this study results if sufficient data was documented in the chart to identify a 
credible source other than the CVC for infection.  
5.4 A Note on Notes 
In mid-2018 Eastern Health enacted a change from paper nursing and physician 
notes to electronic. While not part of the original design of the study the principal 
investigator noted a decline in the fidelity of information, particularly from nursing 
notes with this transition. 
  
In the paper-based documentation, nursing notes were a rich source of data on 
the day-to-day integrity of CVCs for admitted SCT patients. Many complications 
in the study classified as exit site infections were only noted in nursing 
 
52 
documentation, even if treated with topical antibiotics. There was regular 
documentation of line care performed, the presence of early signs and symptoms 
of infection and comments on the functionality and performance of CVCs. As 
charting moved to electronic format the depth of information captured in notes 
thinned and was more frequently associated with a just a single issue (diet, care, 
patient-voiced concerns, etc.). 
 
It may be the case that this change resulted in underreporting of exit site 
infections in the latter phases of data collection.  
5.5 Limitations 
This study is subject to a number of limitations. With the available sample size, 
the study was under-powered to answer the primary outcome with statistical 
significance. The retrospective nature of this chart review limits the data to the 
quality of the documentation, particularly application of the definitions of exit site 
and tunneled-line infections and documentation of risk factors. Additionally, there 
is limited documentation of the occurrences in the interventional radiology suite 
and almost no documentation of interactions between caregivers and CVCs in 
the outpatient period between CVC insertion and admission for SCT. These are 
all sources of information bias within the study. 
A second source of limitation within the study is the retrospective design for the 
pre-intervention group. This makes the control of confounders difficult. It also fails 
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to allow randomization, making the design unable to identify cause-and-effect 
relationships.  
There are also limitations associated with the study population. First, the overall 
number of patients treated in Newfoundland and Labrador annually are low in 
comparison with other hematological oncology centres. This requires a longer 
time horizon to accumulate a sufficient number of patients to meet sample size to 
power the study. Over this length of time clinical practice patterns can change, 
particularly as three physician groups are involved in CVC placement and 
management (Hematology, Interventional Radiology and Infectious Disease). 
This is a source of potential bias in the study. Local population factors and 
clinical practice may limit the generalizability of the data to other centres. 
Finally, we need to consider that these populations are not randomly sampled 
and as such there are many differences in the baseline characteristics of the 
cohorts that may contribute to the differences observed in outcomes. 
5.6 Future Work 
This study was small from the outset given the limited patient population at our 
centre. However, the planned enrollment of this study was truncated by the 
COVID-19 global pandemic and may have limited the overall utility of the results. 
The intention is for this study to resume enrollment under a new principal 
investigator once the pandemic has abated to the point that the SCT program 
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can safely resume. Hopefully a larger sample size also more robust analysis of 
risk factors contributing to CR-BSI. 
 
All the epidemiological studies examining the issue of CVC infectious 
complications in this population are limited to single centre studies. This problem 
is significant in terms of the incidence of cases in this population and the 
morbidity and mortality associated with infections. I would suggest that a 
systematic review and meta-analysis of the existing studies to be a good starting 
point for establishing more robust and consistent data on the risk factors for 
these infectious complications. It is important to identify mechanisms to reduce 
the rate of these infections to protect this population. 
 
Further, in the investigation of the credibility of a modified definition of CR-BSI to 
eliminate oropharyngeal and gastrointestinal agents I would propose a 
prospective trial that combined physical examination and imaging findings with 
culture results to attempt to more definitively identify the source of infections in 
this population to rule out the CVC as the culprit. 
5.7 Conclusions 
 
In summary we have been able to confirm clinical suspicion of a rise in the rate of 
CVC associated infectious complications in SCT patients at Eastern Health in the 
period from July 2017 - June 2018. An etiology was not obviously evident for this 
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increase based on the chart review. In terms of the efficacy of the dual 
interventions we were not able to demonstrate a statistically significant reduction 
in infectious complications. 
 
Risk factor analysis identified a novel harmful risk factor for CR-BSI in patients 
with a history of bacteremia prior to SCT. Previous analysis has failed to identify 
consistent risk factors in this population; however, this study confirmed a single 
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